Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

著者: Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, D-W Kim, Surapol Issaragrisil, Philipp D. le Coutre, Gabriel Étienne, P.E. Dorlhiac‐Llacer, Richard E. Clark, Ian W. Flinn, Hirohisa Nakamae, Breanne Donohue, Weiping Deng, Darshan Dalal, Hans D. Menssen, Hagop M. Kantarjian - Leukemia 2016 被引用: 850